Related Experiment Videos
Optimization of gentamicin therapy in very low birth weight infants
Insights
Optimizing gentamicin therapy for preterm infants: Lower doses (3.5-4 mg/kg/day) are recommended for infants under 1 kg to prevent toxic levels, due to their slower drug clearance and longer half-life.
Area of Science:
- Neonatal Pharmacology
- Pediatric Pharmacokinetics
- Antibiotic Therapy Optimization
Background:
- Gentamicin is a critical antibiotic for treating neonatal infections.
- Optimizing gentamicin dosing in preterm infants is essential to balance efficacy and minimize nephrotoxicity.
- Pharmacokinetic variability in preterm neonates necessitates individualized dosing strategies.
Purpose of the Study:
- To investigate gentamicin pharmacokinetics in preterm infants.
- To determine optimal gentamicin dosing to avoid excessive drug levels and potential nephrotoxicity.
- To identify factors influencing gentamicin clearance and half-life in this population.
Main Methods:
- Studied gentamicin pharmacokinetics in 48 preterm infants (25-37 weeks gestational age).
- Administered intravenous gentamicin twice daily at 5.2 +/- 0.6 mg/kg/day.
- Measured trough and peak gentamicin levels, calculated half-life, clearance, and distribution volume.
Main Results:
- Infants <1 kg had significantly higher gentamicin trough levels (3.1 vs. 2.3 µg/mL) and longer half-lives (7.9 vs. 6.5 hr) compared to infants 1-2.5 kg.
- Lower gentamicin clearance was observed in infants <1 kg (31 vs. 39 mL/kg/hr), explaining higher drug accumulation.
- No significant differences in gentamicin distribution volume or correlations between BUN/gestational age and clearance were found.
Conclusions:
- Gentamicin dose should be reduced to 3.5-4 mg/kg/day for preterm infants <1 kg.
- This dose adjustment aims to prevent excessive gentamicin levels and associated nephrotoxicity.
- Individualized pharmacokinetic monitoring is crucial for safe and effective gentamicin therapy in vulnerable neonates.
Abstract:
In order to optimize gentamicin (G) therapy we studied G pharmacokinetics in 48 preterm infants (gest. age 31.6 +/- 3.4, range 25-37 wk; birth weight 1.5 +/- 0.5 kg, range 0.7-2.5 kg). They received IV G twice daily (5.2 +/- 0.6 mg/kg/day). After at least 2 days of treatment trough and peak levels were measured for 2 successive doses. Trough levels were significantly higher in infants less than 1 kg receiving 5 mg/kg/day than in other infants (1-2.5 kg) who received the same dose (3.1 +/- 1.0 vs. 2.3 +/- 0.5 micrograms/ml; p less than 0.01). Mean G t 1/2 was significantly longer in infants under 1 kg than in those weighing 1-2.5 kg (7.9 +/- 1.9 and 6.5 +/- 1.6 hr, respectively; p less than 0.01). These differences could be attributed to lower G clearance in infants less than 1 kg (31 +/- 6 vs. 39 +/- 8 ml/kg/hr; p less than 0.005). There was no difference in G distribution volume between less than 1 kg and 1-2.5 kg infants (0.35 +/- 0.07 and 0.38 +/- 0.13 L/kg, respectively). A correlation was found between clearance and t 1/2 for the total group (r = 0.57, p less than 0.01). No correlation was detected between BUN and clearance or between gestational age and clearance. Our data suggest that G dose in infants less than 1 kg should be reduced to 3.5-4 mg/kg/day in order to avoid excessive levels associated with nephrotoxicity.